Semaglutide
A closer look at the ingredient in Ozempic and Wegovy.
Open the semaglutide mapStarting mapCompare the care
Compare the care
What can a name or a study tell me?
Names help identify a product. Studies help describe what happened to a group. Neither replaces a conversation about your own care.
Are the medicine names interchangeable?
No. An ingredient can appear in different branded products with different approved uses. The reason for a prescription matters.
The Food and Drug Administration uses the short name FDA. This agency in the U.S. checks medicines for approval.
Approval means FDA has reviewed a medicine’s quality, safety, and how well it works.
Medicine information checked in September 2026 showed different approved uses for products with the same ingredient.
With semaglutide, Ozempic covered type 2 diabetes, an illness involving high blood sugar. Wegovy included weight care.
With tirzepatide, Mounjaro covered diabetes and Zepbound included weight care.
With liraglutide, Victoza covered diabetes and Saxenda included weight care.
Ask about the reason for the prescription alongside the exact product name.
Tirzepatide
Untangle the ingredient in Mounjaro and Zepbound.
Open the tirzepatide mapLiraglutide
Find the difference between Victoza, Saxenda, and other approved versions.
Open the liraglutide mapCan a study tell me my result?
A study gives a group result, not a personal forecast. Look for who joined, how long it lasted, and what the medicine was compared with.
The STEP 1 study included adults with obesity or overweight and a related health condition, without diabetes.
Over 68 weeks, those on semaglutide lost 14.9% of their starting weight on average.
The comparison group lost 2.4% with placebo, a shot without the active medicine. Both groups received advice on eating and physical activity and attended regular visits. The maker funded the study.
That is evidence for the studied product and setting. It is not a promised result for a person choosing online care.
Can I compare drugs using separate studies?
Be careful with that shortcut. Different groups and study lengths can change the picture.
In SURMOUNT-5, which compared the drugs directly, adults with obesity and no diabetes lost 20.2% on tirzepatide and 13.7% on semaglutide over 72 weeks.
Eli Lilly, the maker of tirzepatide, funded this study. People knew which drug they received.
More average weight loss does not answer which medicine fits your health history, budget, or goals. That is a care conversation.
